Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs....

Cijeli opis

Bibliografski detalji

Glavni autori:	Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2019-05-01
Serija:	Rheumatology and Therapy
Teme:	Arthritis Biological DMARDs Rheumatoid arthritis
Online pristup:	http://link.springer.com/article/10.1007/s40744-019-0157-3
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!